Two Phase 1 clinical trials have demonstrated the safety and tolerability of rimteravimab (XVR011), an innovative heavy chain-only antibody treatment for mild-to-moderate COVID-19. The studies, published in PLOS Medicine, evaluated the experimental therapy in both healthy volunteers and hospitalized COVID-19 patients.
Rimteravimab Dose Escalation in Clinical Trials
Single ascending doses tested in healthy volunteers and COVID-19 patients, 2021-2022
Source: Jansen et al., PLOS Medicine 2024 | Georgian Medical Journal News
Novel Antibody Design Shows Safety Profile
Rimteravimab represents an innovative approach to COVID-19 treatment, utilizing Variable Heavy domain of Heavy chains (VHH) technology. According to Dr. Ellen Jansen and colleagues from the research consortium, the antibody consists of two identical VHHs targeting the receptor binding domain of SARS-CoV-2 spike protein, combined with a human IgG1 fragment.
The EXEVIR0102 study enrolled healthy volunteers in a randomized, double-blinded, placebo-controlled design, while the EXEVIR0101 study examined hospitalized COVID-19 patients in an open-label format. Both trials evaluated single intravenous infusions at doses of 250, 500, or 1,000 mg, with safety and tolerability as the primary endpoints. For more clinical updates on emerging therapies, our research team continues monitoring Phase 1 trial developments.
Pharmacokinetics and Immunogenicity Results
The studies evaluated pharmacokinetics as a secondary objective in healthy volunteers and as an exploratory endpoint in COVID-19 patients. Researchers also assessed efficacy parameters including respiratory function and COVID-19 clinical status in hospitalized patients, according to the ClinicalTrials.gov registry.
Immunogenicity was monitored as an exploratory objective across both study populations. The research team emphasized that rimteravimab’s design includes silenced Fc effector functions, potentially reducing immune-mediated side effects while maintaining therapeutic activity against the viral target.
Omicron Variant Challenges Development
Despite promising early results, the planned Part 2 expansion of the EXEVIR0101 study was discontinued due to reduced XVR011 potency against SARS-CoV-2 Omicron BA.2 variant. This development highlights the ongoing challenge of viral evolution in COVID-19 therapeutic development, as documented by the World Health Organization in their variant tracking reports.
The loss of activity against Omicron variants underscores the importance of designing therapeutics with broad neutralizing capacity or rapid adaptability to emerging strains. For comprehensive analysis of new studies addressing variant-resistant treatments, researchers continue investigating next-generation approaches.
Rimteravimab demonstrated acceptable safety and tolerability profiles across all tested doses in both healthy volunteers and hospitalized COVID-19 patients, though development was halted due to reduced efficacy against Omicron variants.
— Dr. Ellen Jansen, Research Consortium (PLOS Medicine, 2024)
Key takeaways
- Two Phase 1 trials successfully demonstrated safety of rimteravimab at doses up to 1,000 mg in healthy volunteers and COVID-19 patients
- The VHH-Fc construct represents an innovative heavy chain-only antibody approach for viral neutralization
- Development was discontinued due to reduced potency against SARS-CoV-2 Omicron BA.2 variant, highlighting variant escape challenges
Frequently asked questions
What makes rimteravimab different from other COVID-19 antibodies?
Rimteravimab uses Variable Heavy domain of Heavy chains (VHH) technology, creating a heavy chain-only antibody with silenced Fc effector functions. This design potentially reduces immune-mediated side effects while maintaining viral neutralization capacity.
Why was the development program halted?
Part 2 of the clinical program was discontinued when researchers discovered that XVR011 lost potency against the SARS-CoV-2 Omicron BA.2 variant. This variant escape is a common challenge in COVID-19 therapeutic development.
What doses were tested in the Phase 1 trials?
Both studies evaluated single intravenous infusions at 250 mg, 500 mg, and 1,000 mg doses. All doses demonstrated acceptable safety and tolerability profiles in the tested populations.
These Phase 1 results contribute valuable insights into heavy chain-only antibody development for infectious diseases, despite the specific challenges posed by SARS-CoV-2 variant evolution. The safety data may inform future VHH-Fc construct designs for other therapeutic targets, while the variant escape findings reinforce the need for broadly neutralizing approaches in pandemic preparedness strategies.
Was this article helpful?
Related Coverage
